We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Allows Greater Flexibility for Biosimilar Licensing, Expert Says
FDA Allows Greater Flexibility for Biosimilar Licensing, Expert Says
April 10, 2012
Companies seeking to market biosimilars may have more success getting their products approved in the U.S. than in other highly regulated markets, thanks to the FDA’s “step-wise” guidance.